Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7771

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7771). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500907771)

Label Image (Lbl500907771)
Levetiracetam USP 1000 mg film-coated tablet label from A-S Medication Solutions. The label indicates each film-coated tablet contains 1000 mg of levetiracetam, with a package of 60 tablets. Storage instructions specify to store at 68 to 77 degrees Fahrenheit. The label includes a lot number and NDC 50090-7771-1.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' showing the percentage of patients achieving response. The x-axis compares Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day groups with sample sizes noted. The y-axis represents the percentage of patients, ranging from 0% to 45%. Bars for Levetiracetam groups show higher response rates (37.1% and 39.6%) than placebo (7.4%), with statistical significance indicated.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding to Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The vertical axis represents the percentage of patients, with bars indicating 6.3% for Placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day. Asterisks denote statistical significance versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to Placebo and Levetiracetam 3000 mg/day. The Placebo group (N=104) shows a responder rate of 14.4%, and the Levetiracetam group (N=180) shows a higher responder rate of 39.4%, with a note indicating statistical significance versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar graph showing responder rates (≥50% reduction from baseline) in Study 4 comparing placebo (19.6%) and Levetiracetam (44.6%). The x-axis labels the groups as Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients, from 0% to 45%. An asterisk indicates a statistically significant difference between Levetiracetam and placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar chart showing the responder rate for patients aged 1 month to less than 4 years in Study 5, comparing placebo and Levetiracetam. The chart displays the percentage of patients achieving a 50% or greater reduction from baseline, with Levetiracetam showing a higher responder rate (43.1%) than placebo (19.6%). The Levetiracetam bar is marked as statistically significant versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar chart showing responder rate (≥50% reduction from baseline) in PGTC seizure frequency per week in Study 7. The chart compares placebo with Levetiracetam, showing approximately 45.2% responder rate for placebo (N=84) and 72.2% for Levetiracetam (N=79), with the Levetiracetam result marked as statistically significant versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam showing its molecular arrangement including a pyrrolidone ring and side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.